Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy

(2016) Zhenfei Li et al.   NATURE

Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer

(2016) Akash Kumar et al.   NATURE MEDICINE

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer

(2016) Himisha Beltran et al.   NATURE MEDICINE

Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer

(2016) Christine Henzler et al.   Nature Communications

Serial blood-based analysis of AR-V7 in men with advanced prostate cancer

(2015) M. Nakazawa et al.   ANNALS OF ONCOLOGY

Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth

(2015) Y. Yamamoto et al.   CLINICAL CANCER RESEARCH

Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer

(2015) Zhenfei Li et al.   NATURE

RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance

(2015) D. T. Miyamoto et al.   SCIENCE

Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy

(2015) Bo Cao et al.   Oncotarget

Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer

(2015) Yuanyuan Qu et al.   Scientific Reports

Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation

(2014) Jonathan I. Epstein et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer

(2014) Z. Yu et al.   CLINICAL CANCER RESEARCH

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Glucocorticoid Receptor Activity Contributes to Resistance to Androgen-Targeted Therapy in Prostate Cancer

(2014) Masis Isikbay et al.   Hormones & Cancer

Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade

(2013) Vivek K. Arora et al.   CELL

Mechanisms of the androgen receptor splicing in prostate cancer cells

(2013) L L Liu et al.   ONCOGENE

TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer

(2013) M. D. Nyquist et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

FoxA1 Specifies Unique Androgen and Glucocorticoid Receptor Binding Events in Prostate Cancer Cells

(2012) B. Sahu et al.   CANCER RESEARCH

Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines

(2012) Y. Li et al.   CANCER RESEARCH

The mutational landscape of lethal castration-resistant prostate cancer

(2012) Catherine S. Grasso et al.   NATURE

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

(2012) Christopher E Barbieri et al.   NATURE GENETICS

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

(2012) Charles J. Ryan et al.   NEW ENGLAND JOURNAL OF MEDICINE

AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression

(2012) Y Li et al.   ONCOGENE

Androgen Receptor Gene Expression in Prostate Cancer Is Directly Suppressed by the Androgen Receptor Through Recruitment of Lysine-Specific Demethylase 1

(2011) Changmeng Cai et al.   CANCER CELL

Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer Progression

(2011) Y. Li et al.   CANCER RESEARCH

Alternatively spliced androgen receptor variants

(2011) Scott M Dehm et al.   ENDOCRINE-RELATED CANCER

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival

(2011) Emma Hörnberg et al.   PLoS One

A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities

(2011) Rong Hu et al.   PROSTATE

Integrative Genomic Profiling of Human Prostate Cancer

(2010) Barry S. Taylor et al.   CANCER CELL

A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth

(2009) Z. Guo et al.   CANCER RESEARCH

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

(2009) C. Tran et al.   SCIENCE

Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance

(2008) S. M. Dehm et al.   CANCER RESEARCH

Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth

(2008) R. B. Montgomery et al.   CANCER RESEARCH

Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer

(2008) R. Hu et al.   CANCER RESEARCH

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

(2008) Gerhardt Attard et al.   JOURNAL OF CLINICAL ONCOLOGY